Clinical Trial Update: Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204) [Phase 3]

View source ↗

Summary

This update reports the completion of a Phase 3 trial (MK-3475-204/KEYNOTE-204) comparing pembrolizumab to brentuximab vedotin in relapsed or refractory classic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Classical Hodgkin Lymphoma
• Hodgkin Lymphoma

Drugs mentioned

• Adcetris (Brentuximab vedotin)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hodgkin Lymphoma | Phase 3 | Status: COMPLETED